Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: clopidogrel Clear all
Not listed Phase 2Phase 3 Interventional

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

NCT03062462
View directory record Official record
Conditions
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
Interventions
Clopidogrel, ticagrelor
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation

NCT00224809
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease
Interventions
Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Bypass Graft, Angiotensin Receptor Blockers, Spironolactone, Aspirin, Clopidogrel, Surgical Ventricular Restoration
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Sep 17, 2026, 4:13 PM EDT
Terminated Phase 3 Interventional Results available

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

NCT00385138
View directory record Official record
Conditions
Atherosclerosis, Acute Coronary Syndrome (ACS)
Interventions
Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
5,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PACT (Platelet Activity After Clopidogrel Termination)

NCT00619073
View directory record Official record
Conditions
Blood Platelets, Clopidogrel
Interventions
clopidogrel + aspirin, placebo, Aspirin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)

NCT00115375
View directory record Official record
Conditions
Congenital Heart Defects, Blood Platelet Disorders
Interventions
Clopidogrel (SR25990)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 24 Months
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 17, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

NCT06821191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
clopidogrel 75 mg, Prasugrel 5 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Anti-platelet + Pembro for H&N Tumors

NCT03245489
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Clopidogrel, acetylsalicylic acid
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 17, 2026, 4:13 PM EDT
Completed No phase listed Observational

The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants

NCT03535883
View directory record Official record
Conditions
Pleural Effusion, Thoracic Effusion
Interventions
Novel Oral Anti-Coagulants
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 17, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional

The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 17, 2026, 4:13 PM EDT
Completed No phase listed Observational

Type 2 Diabetes With Antiplatelet Drugs

NCT05053828
View directory record Official record
Conditions
Type2 Diabetes, Antiplatelet Drugs, Myocardial Infarction, Heart Failure
Interventions
Antiplatelet Drug
Drug
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
173,464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

NCT02833948
View directory record Official record
Conditions
Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Interventions
Acetylsalicylic acid, Clopidogrel, Rivaroxaban
Drug
Lead sponsor
ECRI bv
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

NCT01121224
View directory record Official record
Conditions
Saphenous Vein Graft Atherosclerosis
Interventions
Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label)
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 17, 2026, 4:13 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

NCT01826175
View directory record Official record
Conditions
Acute Coronary Syndrome, Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Optical Coherence Tomography
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 17, 2026, 4:13 PM EDT
Completed No phase listed Observational

T-TAS® wS Method Comparison

NCT06710262
View directory record Official record
Conditions
Antiplatelet Therapy, Healthy Donors, Von Willebrand Disease (VWD)
Interventions
T-TAS PL Assay
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
21 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

NCT00396877
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel (SR25990), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 92 Days
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 17, 2026, 4:13 PM EDT
Not listed No phase listed Observational

Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

NCT00653601
View directory record Official record
Conditions
Bleeding, Thrombosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Sep 17, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin plus clopidogrel, prasugrel or ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy

NCT01852162
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Dabigatran, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers

NCT02922465
View directory record Official record
Conditions
Healthy
Interventions
K-877, Clopidogrel
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 17, 2026, 4:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms

NCT05945563
View directory record Official record
Conditions
Cerebral Aneurysm
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
Interventions
Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 91 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition in Patients With Systolic Heart Failure

NCT01765400
View directory record Official record
Conditions
Systolic Heart Failure
Interventions
Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 17, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

NCT01744288
View directory record Official record
Conditions
Inhibition on Platelet Aggregation
Interventions
Ticagrelor, Clopidogrel, ASA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 17, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

A Polypill for Acute Coronary Syndrome

NCT07032389
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Polypill
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 17, 2026, 4:13 PM EDT